New York State Common Retirement Fund Bio Atla, Inc. Transaction History

New York State Common Retirement Fund

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$1.37 - $3.92 $36,821 - $105,357	-26,877 Reduced 98.6%	383 $1,000
Q1 2024 May 07, 2024	SELL	$1.88 - $3.46 $80 - $148	-43 Reduced 0.16%	27,260 $94,000
Q4 2023 Feb 01, 2024	SELL	$1.27 - $3.18 $127 - $318	-100 Reduced 0.36%	27,303 $67,000
Q3 2023 Nov 07, 2023	BUY	$1.7 - $3.07 $855 - $1,544	503 Added 1.87%	27,403 $47,000
Q2 2023 Aug 07, 2023	BUY	$2.83 - $3.87 $76,127 - $104,103	26,900 New	26,900 $81,000
Q2 2022 Aug 04, 2022	SELL	$2.13 - $5.38 $21,491 - $54,284	-10,090 Reduced 97.66%	242 $1,000
Q4 2021 Feb 02, 2022	BUY	$19.0 - $30.95 $34,181 - $55,679	1,799 Added 21.08%	10,332 $203,000
Q3 2021 Nov 02, 2021	SELL	$29.44 - $43.74 $78,251 - $116,260	-2,658 Reduced 23.75%	8,533 $251,000
Q2 2021 Aug 02, 2021	BUY	$38.07 - $56.17 $167,165 - $246,642	4,391 Added 64.57%	11,191 $474,000
Q1 2021 May 11, 2021	BUY	$32.41 - $70.91 $220,387 - $482,188	6,800 New	6,800 $346,000

17.4M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $16.3M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.